Our data are in line with recent evidence showing that improvement of HD symptoms in the R6/1 mouse model did not correlate with an increase in BDNF.50 In addition to a reduction of BDNF, a hallmark of HD that exacerbates neurodegeneration and neurological symptoms is the pro‐inflammatory activation of microglia induced by mHtt aggregates.51 In this regard, our findings indicate that CM‐hAMSC‐treatment reduced the aggregation of mHtt and reduced the area of activated microglia in the striatum of R6/2 mice. This evidence concerns the gene BDNF and Huntington disease.